Repertoire Partners’s Health Catalyst HCAT Stock Holding History

Repertoire Partners’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,000	Closed	-$10K	–	57
2022 Q3	$10K	Sell	1,000 -49,000	-98%	-$649K	﹤0.01%	38
2022 Q2	$725K	Buy	+50,000	New	+$852K	0.24%	29

Other funds holding HCAT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Daventry Group New York $133M AUM 32.28% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Repertoire Partners's HCAT Position: Q4 2022 in Review

Repertoire Partners sold out of Health Catalyst (HCAT) in Q4 2022, closing a stake of 1,000 shares — an estimated $10K sold.

Repertoire Partners first reported a position in HCAT in Q2 2022 and held it in 2 quarters. The position peaked at $725K in Q2 2022. 166 funds tracked by Wall St. Rank hold HCAT as of Q4 2022.

Repertoire Partners reported no remaining Health Catalyst position as of Q4 2022 after selling out during the quarter.
Repertoire Partners sold 1,000 Health Catalyst shares in Q4 2022, an estimated $10K.
Repertoire Partners first reported a position in Health Catalyst in Q2 2022 and held it in 2 quarters.
Repertoire Partners's Health Catalyst position peaked at $725K in Q2 2022.
166 funds tracked by Wall St. Rank held Health Catalyst as of Q4 2022.

Based on Repertoire Partners's 13F filing for Q4 2022, filed 14 Feb 2023.